FNTB

Protein farnesyltransferase subunit beta · P49356 · FNTB on Sugi Atlas →

102,527 patent compounds predicted against FNTB, 59,379 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Lonafarnib (SCHEMBL19032)	1.00	20/20
Lonafarnib (SCHEMBL94653)	1.00	20/20
Bms-214662 (SCHEMBL94663)	1.00	20/20
Bms-214662 (SCHEMBL134853)	0.74	20/20
Bms-214662 (SCHEMBL134854)	0.74	20/20
SCHEMBL153998	0.72	16/20
SCHEMBL152949	0.69	16/20
Farnesyl Diphosphate (SCHEMBL109441)	1.00	15/20
SCHEMBL155328	1.00	15/20
SCHEMBL155330	1.00	15/20
Farnesyl Diphosphate (SCHEMBL157143)	1.00	15/20
Tipifarnib (SCHEMBL8097)	0.80	15/20
Tipifarnib (SCHEMBL94807)	0.80	15/20
Farnesyl Diphosphate (SCHEMBL153997)	0.72	15/20
Geranyl Diphosphate (SCHEMBL109367)	0.97	14/20
Geranyl Diphosphate (SCHEMBL109368)	0.97	14/20
Geranyl Diphosphate (SCHEMBL152948)	0.94	14/20
Dimethylallyl Diphosphate (SCHEMBL153577)	0.70	14/20
Dimethylallyl Diphosphate (SCHEMBL156447)	0.70	14/20
SCHEMBL153576	0.43	14/20

Clinical trials — most relevant to FNTB by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Comparison of Diagnostic Performance of C-Tb to QuantiFERON®-TB, in Combination With a Safety Assessment of C-Tb vs Tuberculin PPD RT23 SSI	PHASE3	COMPLETED
Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus	PHASE3	COMPLETED
NEO100 and High-Grade Meningioma	PHASE2	RECRUITING
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma	PHASE1/PHASE2	RECRUITING
R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas	PHASE2	COMPLETED
Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC)	PHASE2	COMPLETED
Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria	PHASE2	COMPLETED
Phase II Study of Simvastatin Plus Irinotecan, Fluorouracil, and Leucovorin(FOLFIRI) for Metastatic CRC	PHASE2	COMPLETED
Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis	PHASE2	UNKNOWN
A Phase 2 Study of Farnesyl Transferase Inhibitor (R115777, Tipifarnib) in Patients With Refractory or Relapsed Acute Myeloid Leukemia.	PHASE2	COMPLETED
Comparative Study Between Obeticholic Acid Versus Vitamin E in Patients with Non-alcoholic Steatohepatitis	PHASE2	ACTIVE_NOT_RECRUITING
Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer	PHASE2	COMPLETED
A Study of Bezafibrate in Mitochondrial Myopathy	PHASE2	COMPLETED
Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults	PHASE2	RECRUITING
R115777 in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer	PHASE2	COMPLETED
The Safety and Immunogenicity of a TB Vaccine; MVA85A, in Healthy Volunteers Who Are Infected With HIV	PHASE1	COMPLETED
Use of Blood Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma (HCC)	nan	UNKNOWN
Study of Mycobacterial Infections	nan	RECRUITING
A Study of the Interaction Between Tumor Susceptibility Gene Glycine N-methyltransferase (GNMT) and Lung Cancer	nan	UNKNOWN
Epidemiology of Atherosclerosis	nan	COMPLETED
Association of SGLT2 Inhibitors Therapy With Elastographic and Molecular Markers of Liver Injury in Type 2 Diabetes	nan	COMPLETED
The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients	nan	UNKNOWN
Role of Genetics in Idiopathic Pulmonary Fibrosis (IPF)	nan	UNKNOWN
Statin Therapy and COVID-19 Infection	nan	COMPLETED
FGF19 in Obstructive Cholestasis: Unveil the Signal	nan	UNKNOWN
Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study	nan	COMPLETED
Genetic Modifiers of Cystic Fibrosis (CF) Liver Disease	nan	ACTIVE_NOT_RECRUITING
Statins and the Urinary Proteome	nan	COMPLETED
Mechanisms of Glucose Lowering Effect of Colesevelam HCl	nan	COMPLETED
Vascular Calcification's Risk Factors in Haemodialysis Patients	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a FNTB binder may also engage these)

Protein	Name	Similarity
Q8K2I1	—	1.000	Q8K2I1 →
P49355	—	1.000	P49355 →
Q02293	—	1.000	Q02293 →
Q04903	—	0.994	Q04903 →
P22007	—	0.989	P22007 →
Q8BUY9	—	0.988	Q8BUY9 →
O13782	—	0.987	O13782 →
P41992	—	0.986	P41992 →
P53610	—	0.986	P53610 →
RABGGTB	Geranylgeranyl transferase type-2 subunit bet	0.985	landscape →
Q38920	—	0.985	Q38920 →
P53612	—	0.985	P53612 →
O93830	—	0.984	O93830 →
Q5EAD5	—	0.983	Q5EAD5 →
G4MY67	—	0.982	G4MY67 →
P18898	—	0.980	P18898 →
Q9JJK2	—	0.980	Q9JJK2 →
PGGT1B	Geranylgeranyl transferase type-1 subunit beta	0.979	landscape →
O80642	—	0.979	O80642 →
LANCL2	LanC-like protein 2	0.979	landscape →
Q55DA3	—	0.978	Q55DA3 →
P46960	—	0.978	P46960 →
Q5E9B3	—	0.978	Q5E9B3 →
Q08603	—	0.977	Q08603 →
P20133	—	0.976	P20133 →
Q4WES9	—	0.976	Q4WES9 →
Q10231	—	0.975	Q10231 →
A0A0E0SP71	—	0.975	A0A0E0SP71 →
F1MVX2	—	0.975	F1MVX2 →
P32434	—	0.974	P32434 →